Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminogen II 3.5% M in Dextrose 5% provides essential and non-essential amino acids and dextrose for parenteral nutrition. Amino acids are utilized for protein synthesis and metabolic processes. Dextrose provides a source of calories and energy.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Aminosin II 3.5% M in Dextrose 5% is administered intravenously. Typical adult dose is 1-2 L per day, providing 35-70 g amino acids and 50-100 g dextrose per day, infused at a rate of 0.5-1.5 mL/kg/hour.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Amino acids have variable elimination half-lives (e.g., 0.5-6 h) depending on individual amino acid; dextrose half-life ~1-2 h. Clinical context: Used for continuous infusion, not bolus.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Amino acids are primarily metabolized, with nitrogen excreted as urea (renal, ~80-90%) and ammonia; minimal fecal excretion. Dextrose is fully metabolized to CO2 and water.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution